Oculis to present Phase 2 ACUITY trial results for Privosegtor, DIAMOND program data.

Oculis Holding AG, a biopharmaceutical company, will present clinical trial results for its late-stage pipeline at several upcoming conferences. The results include Phase 2 ACUITY trial data for Privosegtor (OCS-05) in acute optic neuritis and expanded data from the Phase 3 Stage 1 DIAMOND program for OCS-01 eye drops in diabetic macular edema.

Oculis Holding AG, a biopharmaceutical company, will present clinical trial results for its late-stage pipeline at several upcoming conferences. The presentations include data from the Phase 2 ACUITY trial for Privosegtor (OCS-05) in acute optic neuritis and expanded data from the Phase 3 Stage 1 DIAMOND program for OCS-01 eye drops in diabetic macular edema (DME).

The company will present at the Ophthalmology Futures Retina Forum, the EURETINA Innovation Spotlight, the 25th European Society of Retina Specialists (EURETINA) Congress, and the Retina Society Annual Congress. The results will highlight the potential of OCS-01 to benefit various DME patient profiles, including phakic and pseudophakic patients, as well as treatment naïve and previously treated patients.

The Phase 2 ACUITY trial investigating Privosegtor (OCS-05), a potential neuroprotective therapy for acute optic neuritis, will be presented during the late-breaking session at the 25th EURETINA Congress. Previously disclosed headline results from the trial showed clinically meaningful visual function improvement with anatomical neuroprotection benefits in patients treated with Privosegtor, suggesting potential applicability in multiple retinal, neuro-ophthalmological, and neurological conditions.

Additionally, the winner of the annual Ramin Tadayoni Award will be announced during the EURETINA opening ceremony on September 4, 2025. Established by EURETINA in partnership with Oculis, the award honors the legacy of Professor Tadayoni, Oculis’ former Chief Scientific Officer and a renowned retina specialist. This prestigious award promotes innovative research by recognizing an outstanding postgraduate scholar with the potential to make significant advances in understanding and treating retinal diseases.

Details of Oculis’ presentations are as follows:

- Ophthalmology Futures Retina Forum: Is Diabetic Retinopathy the Overlooked Elephant in the Room – Panel Discussion
- Presenter: Riad Sherif, M.D., Chief Executive Officer
- Date/Time: Wednesday, September 3, 2025; 10:00 – 10:30 CEST

- Corporate Presentation
- Presenter: Riad Sherif, M.D., Chief Executive Officer
- Date/Time: Wednesday, September 3, 2025; 14:00 CEST

- EURETINA Innovation Spotlight: Corporate Presentation
- Presenter: Sharon Klier, M.D., Chief Development Officer
- Date/Time: Wednesday, September 3, 2025; 16:20 CEST

- EURETINA: Efficacy and Safety Outcomes over 12 weeks with OCS-01 Eye Drops in DME From DIAMOND Phase 2/3 trial: Focus on Subgroup by Lens Status
- Presenter: Patricio Schlottmann, M.D.
- Session: Free Paper 1 - Diabetes & Vascular Diseases
- Date/Time: Thursday, September 4, 2025; 10:57 – 11:03 CEST

- Efficacy and Safety Outcomes over 12 weeks with OCS-01 Eye Drops in DME From DIAMOND-Stage 1 trial: Focus on Subgroup by Prior Treatment Status
- Presenter: Veeral Sheth, M.D., MBA, FACS, FASRS
- Session: Free Paper 1 - Diabetes & Vascular Diseases
- Date/Time: Thursday, September 4, 2025; 11:03 – 11:09 CEST

- Improved Low Contrast Visual Acuity and Reduction in Retinal Ganglion Cell Loss with Privosegtor in Acute Optic Neuritis: Results from a Multicenter Randomized Placebo-Controlled Double-Masked Trial
- Presenter: Sophie Bonnin, M.D.
- Session: Euretina Session 7 - First Time Clinical Trials & Late Breaking Session
- Date/Time: Friday, September 5, 2025; 15:57 – 16:03 CEST

- Retina Society Annual Congress: Efficacy and Safety Outcomes Over 12 Weeks with OCS-01 Eye Drops in DME from DIAMOND Phase 2/3 Trial: Focus on Subgroup by Lens Status
- Presenter: Diana Do, M.D.
- Session: Diabetes 1
- Date/Time: Thursday, September 11, 2025; 16:42 – 16:47 CDT

The presentations will provide valuable insights into the company’s pipeline and the potential of its innovative treatments for ophthalmic and neuro-ophthalmic diseases. These results are expected to attract significant attention from investors and healthcare professionals alike.

References:
[1] https://www.globenewswire.com/news-release/2025/09/01/3142014/0/en/Oculis-to-Present-Clinical-Trial-Results-in-Diabetic-Macular-Edema-and-Acute-Optic-Neuritis-at-Ophthalmology-Conferences.html